The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. For example, the Group significantly contributed to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
Internship: Mr Fanou Ako Anoumou, University Lyon I21/02/2019 – 30/06/2019
Mr Anoumou will complete a 4-month internship within the Screening Group as part of the second year of his master’s degree in the field of public health. He will be involved in the CanScreen5 project for Africa.
Meeting: Lung Cancer Europe Roundtable, Brussels, Belgium19/02/2019
Dr Andre Carvalho participated in this meeting, to be updated about the European Union policy, current research, and new innovations and recommendations.
Training course for master trainers in cervical cancer prevention, early detection, and treatment, Barshi, India18/02/2019 – 22/02/2019
This training course, with 13 participants from Morocco was organized in collaboration with the Lalla Salma Foundation and the Nargis Dutt Memorial Cancer Hospital (NDMCH), India.
|Randall T.C., Sauvaget C., Muwonge R., Trimble E.L., Jeronimo J. Authors response to Papoutsis and colleagues letter to the editor regarding: Worthy of further consideration: An updated meta-analysis to address the feasibility, acceptability, safety and efficacy of thermal ablation in the treatment of cervical cancer precursor lesions. Prev Med. 2019 Feb 10.|
|Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow up cohort study. Basu P., Muwonge R., Bhatla N., Nene B.M., Joshi S., Esmy P.O., Poli U.R.R., Joshi G., Verma Y., Zomawia E., Shastri S.S., Pimple S., Anantharaman D., Prabhu P.R., Hingmire S., Sauvaget C., Lucas E., Pawlita M., Gheit T., Jayant K., Malvi S.G., Siddiqi M., Michel A., Butt J., Sankaran S., Rameshwari Ammal Kannan T.P., Varghese R., Divate U., Willhauck-Fleckenstein M., Waterboer T., Muller M., Sehr P., Vashist S., Mishra G., Jadhav R., Thorat R., Tommasino M., Pillai M.R., Sankaranarayanan R.; Indian HPV vaccine study group. Papillomavirus Res. 2019 Jan 31. pii: S2405-8521(18)30133-2.|
|DA Silva E.M., Kay A., Lobato C., Muwonge R., Zoulim F., Brites C., Parana R., Trepo C. Non-F HBV/HDV-3 co-infection is associated with severe liver disease in Western Brazilian Amazon. J Med Virol. 2019 Jan 29.|